Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Hematology
Disease Category: Mantle Cell Lymphoma
Location: United States, CA
A Phase II Study of Weekly Maintenance Bortezomib and Rituximab in Mantle Cell Lymphoma post Autologous Hematopoietic Cell Transplantation
You have been asked to take part in this research study because you have mantle cell lymphoma and have no evidence of disease after having had an autologous hematopoietic cell transplant. The purpose of this study is to evaluate the effectiveness of maintenance therapy with bortezomib (Velcade) and rituximab after high dose chemotherapy and autologous hematopoietic cell transplantation in research participants with mantle cell lymphoma.
Maintenance chemotherapy is treatment that is given to help keep the mantle cell lymphoma from coming back. You treatment on this study is expected to last 24 months. After your treatment on this study is over, your medical condition will be followed on this study for up to 3 years.
Patient Inclusion/Exclusion Criteria:
- See http://clinicaltrials.coh.org for additional information.
City of Hope
1500 East Duarte Road
Duarte, CA 91010-3000
Phone: 866-896-HOPE (4673)
Research Center Information: City of Hope
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these